Immunoregulating properties of peptides related to tumor rejection antigens:: Effect on human monocytes and natural killer cells

被引:6
作者
Pérez-Díez, A [1 ]
Martínez-Crespo, A [1 ]
Pérez-Mediavilla, LA [1 ]
Santiago, E [1 ]
López-Moratalla, N [1 ]
机构
[1] Univ Navarra, Dept Biochem, E-31080 Pamplona, Spain
关键词
cytokine; DNase; MAGE; nitric oxide synthase; NK activity; tyrosinase;
D O I
10.1097/00002371-200003000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The authors analyzed the effect of several 15-amino acid peptides with sequences related to tumor-rejection antigens, tyrosinase, and the MAGE family on peripheral blood mononuclear cells from healthy donors cultured for periods of 1 to 7 days. Some of these peptides promoted stimulation of monocytes, manifested by phenotypic changes, release of interleukin (IL)-1a, IL-6, and tumor necrosis factor-or, and induction of nitric oxide synthase on differentiated CD14(++)/(+)CD16(+)DR(++) monocytes. An increase in the percentage of cytotoxic monocytes (CD14(+/-)CD16(+)) containing granule-associated DNase activity was also observed. Active peptides induced the release of IL-2 and interferon-gamma. Nonspecific natural killer and lymphokine-activated killer cell-mediated cytotoxicity was also observed against classical target cell lines (K-562 and Daudi) and allogenic melanoma cell lines AC and BE, together with an increase in granule-associated DNase in the natural killer cell-enriched population. Monocytes were needed to enhance this innate response, because peptides failed to induce the release of IL-2 on monocyte-depleted peripheral blood mononuclear cells. Data show an enhancement of the rapid innate immune response by peptides related to tumor rejection antigens and suggest that they could also determine the nature of a slow and more definitive specific immune response against tumor cells.
引用
收藏
页码:215 / 224
页数:10
相关论文
共 47 条
[1]  
ANDREESEN R, 1990, CANCER RES, V50, P7450
[2]  
BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
[4]  
CUI SJ, 1994, CANCER RES, V54, P2462
[5]  
Czerniecki BJ, 1997, J IMMUNOL, V159, P3823
[6]   PHASE-I TRIAL OF INTRAVENOUS-INFUSION OF EXVIVO-ACTIVATED AUTOLOGOUS BLOOD-DERIVED MACROPHAGES IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER - TOXICITY AND IMMUNOMODULATORY EFFECTS [J].
FARADJI, A ;
BOHBOT, A ;
SCHMITTGOGUEL, M ;
ROESLIN, N ;
DUMONT, S ;
WIESEL, ML ;
LALLOT, C ;
EBER, M ;
BARTHOLEYNS, J ;
POINDRON, P ;
MORAND, G ;
WITZ, JP ;
OBERLING, F .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (05) :319-326
[7]   Elements of immunity - The instructive role of innate immunity in the acquired immune response [J].
Fearon, DT ;
Locksley, RM .
SCIENCE, 1996, 272 (5258) :50-54
[8]  
FEINMAN R, 1987, J IMMUNOL, V138, P635
[9]   LOSS OF HLA CLASS-I ANTIGENS BY MELANOMA-CELLS - MOLECULAR MECHANISMS, FUNCTIONAL-SIGNIFICANCE AND CLINICAL RELEVANCE [J].
FERRONE, S ;
MARINCOLA, FM .
IMMUNOLOGY TODAY, 1995, 16 (10) :487-494
[10]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95